A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
NotableEligibility criteria expanded, about 43 wordsShow 5 more changesShow less
Enrollment closed, study ongoing
Trial sites expanded: 8 → 35 locations
Enrollment target: estimated 448 to confirmed 465
Primary and study completion dates: May 31, 2027 to May 3, 2027
Study description revised
MinorStudy sites: 2 to 8
Primary and study completion dates: Sep 2, 2027 to May 31, 2027
v4
MinorPrimary and study completion dates: Jul 27, 2027 to Sep 2, 2027v3
NotableEligibility criteria expanded, about 22 words
Primary endpoints: 12 to 15
Study sites: 32 to 2
Primary and study completion dates: Aug 2, 2027 to Jul 27, 2027
v2
Study First Submitted
Notable: the plan changed
Minor: routine updates
Endpoints
Primary
Part 1 and 2: Number of participants reporting solicited administration site adverse events (AEs)
Timeframe: During the 7 days follow-up period post-Dose 1 (study intervention administered at Day 1)
Part 1 and 2: Number of participants reporting solicited administration site AEs
Timeframe: During the 7 days follow-up period post-Dose 2 (study intervention administered at Day 61)
Part 1 and 2: Number of participants reporting solicited systemic AEs
Timeframe: During the 7 days follow-up period post-Dose 1 (study intervention administered at Day 1)
Part 1 and 2: Number of participants reporting unsolicited AEs
Timeframe: During the 30 days follow-up period post-Dose 1 (study intervention administered at Day 1)
Part 1 and 2: Number of participants reporting any immediate unsolicited AEs
Timeframe: During the 60 minutes follow-up period post-Dose 1 (study intervention administered at Day 1)
Part 1 and 2: Number of participants reporting serious adverse events (SAEs)
Timeframe: From Day 1 (Dose 1 administration) until Day 426 (end of follow-up)
Part 1 and 2: Number of participants reporting potential immune-mediated diseases (pIMDs) leading to study withdrawal
Timeframe: From Day 1 (Dose 1 administration) until Day 426 (end of follow-up)
Part 1 and 2: Number of participants reporting medically-attended adverse events (MAAEs) leading to study withdrawal
Timeframe: From Day 1 (Dose 1 administration) until Day 426 (end of follow-up)
Part 1 and 2: Number of participants reporting AEs leading to study withdrawal
Timeframe: From Day 1 (Dose 1 administration) until Day 426 (end of follow-up)
Part 1: Number of participants with hematology or biochemistry abnormalities or changes in baseline value
Timeframe: At 7 days post-Dose 1 (Day 8) compared with baseline (pre-Dose 1, Day 1)
Part 2: Incidence rate (IR) of the first occurrence of a urine culture confirmed UTI due to E. coli in the investigational group compared to the IR in placebo group
Timeframe: From 14 days (Day 75) up to 12 months (Day 426) post-Dose 2
Secondary (2)
Part 2: IR of the total number of occurrences of urine culture confirmed UTIs due to E. coli in the investigational group compared to the IR in placebo group
Part 2: IR of the first occurrence of a urine culture confirmed UTI due to E. coli in the investigational group compared to the IR in placebo group
Arms and interventions
Part 1 Group A1/A2Experimental
Participants receive candidate UTI vaccine low dose formulation 1 or placebo on Day 1 and Day 61.
Part 1 Group B1/B2Experimental
Participants receive candidate UTI vaccine low dose formulation 2, or placebo on Day 1 and Day 61.
Part 1 Group C1/C2Experimental
Participants receive candidate UTI vaccine medium dose formulation 1, or placebo on Day 1 and Day 61.
Part 1 Group D1/D2Experimental
Participants receive candidate UTI vaccine medium dose formulation 2, or placebo on Day 1 and Day 61.
Part 1 Group E1/E2Experimental
Participants receive candidate UTI vaccine high dose formulation 1, or placebo on Day 1 and Day 61.
Part 1 Group F1/F2Experimental
Participants receive candidate UTI vaccine high dose formulation 2, or placebo on Day 1 and Day 61.
Part 2 Group 1Experimental
Participants receive the candidate UTI vaccine highest tolerated dose (HTD) formulation 2, tested in Part 1 of the study, on Day 1 and Day 61.
Part 2 Group 2Placebo comparator
Participants receive placebo on Day 1 and Day 61.
Combination products: Candidate UTI vaccine low dose formulation 1, Candidate UTI vaccine low dose formulation 2, Candidate UTI vaccine medium dose formulation 1, Candidate UTI vaccine medium dose formulation 2, Candidate UTI vaccine high dose formulation 1, Candidate UTI vaccine high dose formulation 2, Candidate UTI vaccine HTD formulation 2, Placebo
Sites
35 sites in 6 countries
Spain 11, United States 9, Belgium 6, Argentina 4, South Africa 4, Puerto Rico 1